等待开盘 09-02 09:30:00 美东时间
-0.259
-6.34%
Nasus Pharma (NSRX) on Wednesday said Chief Financial Officer, Eyal Rubin will be leaving the company to pursue a new opportunity outside the life science industry. Rubin will remain with Nasus throu...
08-19 19:05
Nasus Pharma Ltd. announced that Chief Financial Officer Eyal Rubin will leave the company to pursue a new opportunity outside the life sciences industry. Rubin will remain with the company until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has been with Nasus since its inception and has over 15 years of financial experience, including working with public and pri...
08-19 11:00
Nasus Pharma Ltd. press release (NSRX): 1H Non-GAAP EPS of -$0.54. Six months ended June 30, 2026, net loss totaled $5.94M. Research and development expenses increased to $2.59M while general and admi...
08-17 22:57
Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the same period last year.
08-17 20:15
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady wi...
07-28 19:33
Nasus Pharma Ltd. announced that its management will present at the Zacks Life Sciences Investor Forum on June 24-25, 2026. The virtual event will feature live, interactive sessions where investors can submit questions to management. Nasus Pharma, a clinical-stage company, is developing innovative intranasal powder products for acute medical conditions. Its NS002 product is a needle-free epinephrine option for anaphylaxis patients. The company’s ...
06-22 12:00
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a
06-09 20:02
Nasus Pharma announced positive preclinical results for NS003, its intranasal powder formulation of ondansetron, showing comparable pharmacokinetics and safety to IV ondansetron in animal studies. The company plans to initiate a first-in-human PK study in Q3 2026, targeting unmet needs in chemotherapy and post-operative nausea and vomiting.
06-09 12:00
Nasus Pharma will host a virtual KOL event on June 10, 2026, featuring Michael S. Blaiss, MD, and Joel Brooks, DO, MPH, to discuss anaphylaxis treatment needs. The event will highlight NS002, the company's epinephrine intranasal powder candidate, which shows faster absorption than EpiPen®. NS002 aims to provide a needle-free alternative for anaphylaxis treatment, addressing challenges faced by pediatric patients. The event includes a Q&A session ...
06-01 12:00
Replimune涨-62.61%;Nasus Pharma Ltd.涨-15.91%;雷亚电子涨-15.87%
04-13 08:10